{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:30:46Z","timestamp":1794317446482,"version":"4.9.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgme.2020.07.007","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T19:11:15Z","timestamp":1597518675000},"page":"219-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study"],"prefix":"10.1016","volume":"131","author":[{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan","family":"Nedd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damara","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Skuban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.07.007_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0010","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"a-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2016"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0020","author":"Amicus Therapeutics, Inc"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2016.07.001","article-title":"Fabry disease: a disorder of childhood onset","volume":"64","author":"Schiffmann","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis","volume":"35","author":"Alegra","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0050","first-page":"71","article-title":"Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders","volume":"15","author":"Hendriksz","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0055","doi-asserted-by":"crossref","first-page":"A638","DOI":"10.1016\/S1098-3015(10)67081-7","article-title":"Economic impacts of the Fabry-Anderson disease treatment","volume":"11","author":"De Portu","year":"2008","journal-title":"Value Health"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2020.07.007_bb0060","article-title":"Burden of disease in patients with Fabry disease-economic burden of health care resources consumption","volume":"34","author":"Santamaria","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0075","series-title":"Galafold [Prescribing Information]","year":"2020"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin. Pharmacol. Drug Devel."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/21678707.2018.1469978","article-title":"Migalastat for the treatment of Fabry disease","volume":"6","author":"Sunder-Plassmann","year":"2018","journal-title":"Expert Opin. Orphan Drugs."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0110","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. A. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0115","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0130","first-page":"7","article-title":"Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment naive or formerly treated with agalsidase beta or agalsidase alfa","volume":"23","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0135","first-page":"2090","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","volume":"32","author":"Lenders","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study","volume":"34","author":"Madsen","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0150","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0155","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/495349","article-title":"Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications","volume":"2011","author":"Katholi","year":"2011","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0160","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ajh.2010.80","article-title":"Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis","volume":"23","author":"Pierdomenico","year":"2010","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0165","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0175","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14017431.2017.1332383","article-title":"Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study","volume":"51","author":"Madsen","year":"2017","journal-title":"Scand. Cardiovasc. J."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0190","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"Muntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0215","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Neurological effects of enzyme replacement therapy in Fabry disease","author":"Schiffmann","year":"2006"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0230","series-title":"Replagal [Summary of Product Characteristics]","year":"2016"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0235","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0245","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Demographics of FOS \u2013 the Fabry Outcome Survey","author":"Beck","year":"2006"},{"key":"10.1016\/j.ymgme.2020.07.007_bb0250","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.07.007_bb0260","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:28:53Z","timestamp":1761089333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":51,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1096719220301761"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}